Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.85 Insider Own0.80% Shs Outstand150.06M Perf Week0.87%
Market Cap4.87B Forward P/E- EPS next Y-0.25 Insider Trans-25.47% Shs Float148.96M Perf Month-49.18%
Income-127.30M PEG- EPS next Q-0.18 Inst Own99.50% Short Float3.15% Perf Quarter-55.99%
Sales640.40M P/S7.60 EPS this Y-275.00% Inst Trans-0.27% Short Ratio3.24 Perf Half Y-52.52%
Book/sh9.14 P/B3.55 EPS next Y35.90% ROA-6.70% Target Price51.60 Perf Year-55.72%
Cash/sh5.14 P/C6.31 EPS next 5Y- ROE-9.10% 52W Range27.78 - 80.71 Perf YTD-59.12%
Dividend- P/FCF- EPS past 5Y12.90% ROI-5.90% 52W High-59.79% Beta1.87
Dividend %- Quick Ratio4.80 Sales past 5Y28.30% Gross Margin76.50% 52W Low16.81% ATR3.66
Employees1300 Current Ratio5.00 Sales Q/Q-4.60% Oper. Margin-27.00% RSI (14)29.28 Volatility8.46% 8.25%
OptionableYes Debt/Eq0.26 EPS Q/Q-100.00% Profit Margin-19.90% Rel Volume1.59 Prev Close31.19
ShortableYes LT Debt/Eq0.21 EarningsFeb 24 BMO Payout- Avg Volume1.45M Price32.45
Recom2.50 SMA20-15.36% SMA50-45.85% SMA200-48.99% Volume2,299,221 Change4.04%
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Nov-01-13Reiterated Mizuho Neutral $30 → $33
Oct-30-13Initiated FBR Capital Mkt Perform $31
May-24-13Reiterated UBS Buy $32 → $37
May-24-13Downgrade MKM Partners Neutral → Sell
Apr-18-13Downgrade Mizuho Buy → Neutral $30 → $26
Feb-12-16 06:04AM  5 Breakout Stocks to Trade for Big Gains at TheStreet
Feb-11-16 02:15PM  Alkermes' ALKS 3831 in 2nd Phase III Study for Schizophrenia
Feb-10-16 08:30AM  Who Will Come Out On Top As Flu Season Draws Down Accesswire
07:00AM  Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia Business Wire
Feb-09-16 08:36AM  Alkermes CEO Richard Pops Isn't Giving Up On Breakthrough Depression Drugs at Forbes
Feb-04-16 08:59AM  Why Did Biotech Fall Off a Cliff in January? at Motley Fool
Feb-02-16 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
Jan-28-16 03:29PM  Alkermes short bets built up ahead of depression drug setback -5.34%
Jan-27-16 03:25PM  Alkermes Initiates Early-Stage Study on Alzheimer's Drug -6.88%
Jan-25-16 07:07AM  Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 at noodls
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Business Wire
Jan-24-16 02:00PM  8 Things That Could Lift Biotech Stocks Out of Bear Market at TheStreet
Jan-23-16 10:15AM  4 Stocks That Punished Shareholders Last Week at 24/7 Wall St.
Jan-22-16 03:10PM  Alkermes Hit 52-Week Low on Unfavorable Phase III Data +7.33%
01:11PM  Alkermes Learns Makeovers Aren't Easy at Bloomberg
Jan-21-16 09:42PM  [$$] Business Watch at The Wall Street Journal -44.24%
06:21PM  Why Alkermes, Scholastic, and MGIC Investment Slumped Today at Motley Fool
01:40PM  Why These 5 Stocks Are Plummeting Today at Insider Monkey
01:13PM  [$$] Alkermes Depression Drug Disappoints at The Wall Street Journal
01:05PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Alkermes plc Business Wire
01:02PM  Alkermes Hits Two-Year Low On Depression Drug Failure at Investor's Business Daily
12:19PM  Alkermes downgraded by Morgan Stanley and JP Morgan
11:37AM  Alkermes Falls Most Since 2002 as Depression Drug Trials Fail at Bloomberg
11:19AM  [$$] Five Pharma Picks for Another Volatile Year at Barrons.com
11:18AM  Jim Cramer -- Alkermes Is a Big Disappointment Today at TheStreet
11:13AM  Here's Why Alkermes' Stock Is Tanking Today at Motley Fool
10:29AM  Alkermes (ALKS) Stock Plunges on Depression Treatment's Trial Results at TheStreet
09:55AM  Cramer's Stop Trading: If oil spikes
09:37AM  Biotech Faces New Trial With Alkermes Stumble at The Wall Street Journal
09:28AM  Stocks to Watch: Verizon, FireEye, Kinder Morgan, Southwest at The Wall Street Journal
09:15AM  Why Alkermes Top-Line Results Might Not Be as Bad as Once Thought at 24/7 Wall St.
08:42AM  Alkermes shares plunge after drug misses trial goals at MarketWatch
08:27AM  Alkermes Depression Drug Failure Crimps Future Growth Outlook at TheStreet
07:13AM  Alkermes depression drug fails in two late-stage studies Reuters
07:02AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure
07:00AM  Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder Business Wire
Jan-13-16 04:25PM  Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus -6.10%
Jan-12-16 11:30AM  A health care proposal for presidential hopefuls: Why not tackle alcoholism? at bizjournals.com
Jan-08-16 08:27AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : January 8, 2016
Jan-05-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare Conference Business Wire
02:36PM  2016 Stock Picks From Mott Capital: Alkermes, Tesla, Disney, More at TheStreet
12:36PM  Alkermes, Tesla & Disney Shares Set for Strong 2016 Performances at TheStreet
Jan-04-16 02:45PM  Alkermes Upgraded to Hold on Encouraging Portfolio Update -5.73%
Dec-28-15 05:39PM  Alkermes, American Water Works Beat The Stock Market at Investor's Business Daily
Dec-26-15 12:30PM  Sell These 6 Biotech Stocks Now Before It's Too Late at TheStreet
Dec-23-15 11:51AM  Pharma: What the Doctor ordered for 2016
Dec-18-15 12:48AM  A Look at FDGRXs Historical Portfolio through November 2015
Dec-17-15 02:20PM  Alkermes Hits 52 Week High on Pipeline Update & Aristada
Dec-16-15 07:00AM  Alkermes Announces Achievement of Milestones for CNS Medicines in Proprietary Product and Pipeline Portfolio Business Wire +8.12%
Dec-15-15 11:20AM  Massachusetts biotechs behind one-in-six drugs approved by FDA this year at bizjournals.com
Dec-08-15 01:16PM  ALKERMES PLC. Financials
12:07PM  Alexion Tops IBBs Large-Caps on Release of New Research Data
Dec-07-15 03:45PM  How Are IBBs American Depositary Receipts Performing?
Dec-02-15 08:59AM  Is Alkermes Plc (ALKS) A Good Stock To Buy? at Insider Monkey
Nov-27-15 08:36AM  Europe Approved Biogens Elocta, Topped XBIs Large-Cap Stocks
Nov-24-15 05:24PM  Is Snap-on Incorporated (SNA) A Good Stock To Buy? at Insider Monkey
07:04AM  How to stop Pfizers faux-Irish tax ripoff at MarketWatch
Nov-18-15 03:01PM  Amgen Rises by 2% as XBIs Large-Cap Stocks Rally
Nov-16-15 02:45PM  No Snake Oil in These Four Pharmaceutical Stocks at TheStreet
Nov-11-15 04:00PM  Alkermes Corporate Presentation to be Webcast at the Jefferies 2015 London Healthcare Conference Business Wire
Nov-04-15 02:00PM  While Valeant crashes, this biotech has taken the opposite approach and is soaring
01:11PM  This could be the cure for drug crisis in America's prisons
Nov-03-15 04:00PM  Alkermes Corporate Presentation to Be Webcast at the Credit Suisse 24Th Annual Healthcare Conference Business Wire
09:23AM  Woodford Investment Management Has A Lot Riding On These 5 Stocks at Insider Monkey
Oct-30-15 08:19AM  Why biotech could be on the verge of a rebound
Oct-29-15 03:00PM  Edited Transcript of ALKS earnings conference call or presentation 29-Oct-15 12:30pm GMT +6.26%
08:37AM  Alkermes reports 3Q loss
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q3 2015 Alkermes Plc Earnings Release - Before Market Open
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:01AM  Alkermes plc Reports Third Quarter 2015 Financial Results Business Wire
07:00AM  Alkermes Announces Positive Clinical Trial Results and Streamlined Registration Pathway for ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
Oct-28-15 09:34AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : October 28, 2015
Oct-27-15 01:25PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : October 27, 2015
Oct-22-15 04:00PM  Alkermes to Host Conference Call to Discuss Third Quarter 2015 Financial Results Business Wire
Oct-16-15 09:48AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure
Oct-15-15 01:21PM  Market Responses to the FDAs Approval of Alkermess Aristada
Oct-12-15 03:19PM  Alkermess Multi-Pronged Strategy for Its Aristada Launch
03:16PM  Alkermess Aristada Demonstrates High Efficacy as Schizophrenia Therapy
03:15PM  Alkermess Aristada and Its FDA Approval for Schizophrenia
Oct-09-15 03:44PM  World Mental Health Day: De-Stress with 4 Stocks
Oct-08-15 06:00AM  Jim Cramer's Top Takeaways: Alkermes, Yum! Brands, Novocure at TheStreet
Oct-07-15 10:28AM  Alkermes (ALKS) Stock Price Target Upped at Barclays at TheStreet
07:00AM  Early Warning Signs of Schizophrenia Are Not Acted on Soon Enough, According to New Survey of Psychiatrists and Caregivers Business Wire
Oct-06-15 08:34PM  FDA Approves Alkermes' Schizophrenia Treatment Aristada at The Wall Street Journal
09:31AM  These Two Stocks Are in the Spotlights and Hedge Funds Suggest One of Them is a Buy at Insider Monkey
07:30AM  Alkermes Plc to Discuss FDA Approval of ARISTADAT for Treatment of Schizophrenia Call scheduled for 7:30 am ET today
06:03AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-05-15 08:38PM  ADDING MULTIMEDIA FDA Approves ARISTADA for Treatment of Schizophrenia Business Wire
08:30PM  U.S. FDA approves Alkermes' schizophrenia drug Aristada Reuters
08:14PM  Alkermes Shares Rise on U.S. FDA Approval of Schizophrenia Drug at Bloomberg
07:53PM  Alkermes earns FDA approval for long-acting, injectable schizophrenia drug at bizjournals.com
Oct-02-15 12:32PM  Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices at TheStreet
10:44AM  Alkermes Plc Earnings Q2, 2015
Oct-01-15 12:06AM  Alkermes and Incyte Outperform in Large-Cap Space
Sep-30-15 02:40PM  Technician Picks Oversold Biotechs for Large Potential Trading Bounces at 24/7 Wall St. +6.52%
02:08PM  Endo Led IBBs Pharmaceutical Stocks in Week Ending September 18
Sep-25-15 10:06AM  Akorns Revenue
10:06AM  Alnylam and United Therapeutics: Worst Performers of Mid-Cap
09:50AM  3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness at 24/7 Wall St.
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLOOM FLOYD EDirectorFeb 08Option Exercise18.2920,000365,800128,881Feb 10 05:17 PM
MITCHELL PAUL JDirectorFeb 04Option Exercise18.292,00036,58010,000Feb 04 05:13 PM
MITCHELL PAUL JDirectorFeb 04Sale32.812,00065,6208,000Feb 04 05:13 PM
MITCHELL PAUL JDirectorJan 04Option Exercise18.292,00036,58010,000Jan 04 06:46 PM
BREYER ROBERT ADirectorJan 04Sale77.332,000154,66035,156Jan 04 06:44 PM
MITCHELL PAUL JDirectorJan 04Sale77.332,000154,6608,000Jan 04 06:46 PM
Stejbach MarkChief Commercial OfficerDec 28Option Exercise17.3010,000173,00029,564Dec 28 05:05 PM
Stejbach MarkChief Commercial OfficerDec 28Sale80.2410,000802,39219,564Dec 28 05:05 PM
Cooke ShanePresident, Alkermes plcDec 23Option Exercise14.6018,000262,80068,240Dec 23 05:22 PM
Cooke ShanePresident, Alkermes plcDec 23Sale77.2318,0001,390,09650,240Dec 23 05:22 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 07Option Exercise18.6037,500697,500590,997Dec 08 05:37 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 07Sale72.0637,5002,702,433553,497Dec 08 05:37 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 01Option Exercise18.6010,000186,000151,324Dec 02 06:12 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 01Option Exercise18.6050,000930,000603,497Dec 02 06:17 PM
Stejbach MarkChief Commercial OfficerDec 01Option Exercise17.3018,000311,40037,564Dec 02 06:20 PM
BREYER ROBERT ADirectorDec 01Sale73.462,000146,92037,156Dec 02 06:00 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 01Sale72.1810,000721,768141,324Dec 02 06:12 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 01Sale72.2950,0003,614,344553,497Dec 02 06:17 PM
Stejbach MarkChief Commercial OfficerDec 01Sale72.1818,0001,299,20919,564Dec 02 06:20 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 24Option Exercise18.115,52399,99455,380Nov 24 05:44 PM
Cooke ShanePresident, Alkermes plcNov 23Option Exercise14.6018,000262,80068,240Nov 24 05:16 PM
Cooke ShanePresident, Alkermes plcNov 23Sale72.6218,0001,307,09550,240Nov 24 05:16 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 10Option Exercise15.9510,000159,50059,857Nov 12 05:18 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 10Sale72.3410,000723,39549,857Nov 12 05:18 PM
Brown Iain MichaelVP, Finance & CAONov 04Option Exercise18.606,178114,91144,867Nov 04 05:45 PM
Stejbach MarkChief Commercial OfficerNov 02Option Exercise17.3018,000311,40037,964Nov 04 05:36 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Nov 02Option Exercise20.792,68755,86336,633Nov 04 05:41 PM
Stejbach MarkChief Commercial OfficerNov 02Sale72.0618,0001,297,16819,964Nov 04 05:36 PM
BREYER ROBERT ADirectorNov 02Sale71.802,000143,60039,156Nov 04 05:39 PM
Brown Iain MichaelVP, Finance & CAOOct 29Option Exercise18.6010,822201,28949,511Oct 30 05:27 PM
Brown Iain MichaelVP, Finance & CAOOct 29Sale69.9910,822757,43238,689Oct 30 05:27 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 13Option Exercise13.0620,000261,20071,357Oct 14 05:29 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 13Sale59.7820,0001,195,51651,357Oct 14 05:29 PM
Cooke ShanePresident, Alkermes plcOct 05Option Exercise0.0012,500053,140Oct 07 05:05 PM
BREYER ROBERT ADirectorOct 02Sale60.001,48489,04041,156Oct 05 05:41 PM
BREYER ROBERT ADirectorOct 01Sale60.0051630,96042,640Oct 05 05:41 PM
Cooke ShanePresident, Alkermes plcSep 23Option Exercise14.6018,000262,80058,640Sep 24 05:22 PM
Cooke ShanePresident, Alkermes plcSep 23Sale67.0918,0001,207,63140,640Sep 24 05:22 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 17Option Exercise18.6010,000186,000148,680Sep 17 05:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Option Exercise18.6050,000930,000592,917Sep 17 05:08 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 17Sale71.2010,000711,951138,680Sep 17 05:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Sale71.2750,0003,563,261542,917Sep 17 05:08 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 15Option Exercise13.0620,000261,20068,713Sep 15 05:09 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 15Sale71.1020,0001,421,97248,713Sep 15 05:09 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 11Option Exercise18.115,52399,99419,633Sep 15 05:14 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 10Option Exercise18.6010,000186,000148,680Sep 10 05:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 10Option Exercise18.6050,000930,000592,917Sep 10 05:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 10Sale67.6110,000676,052138,680Sep 10 05:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 10Sale67.5750,0003,378,387542,917Sep 10 05:06 PM
BREYER ROBERT ADirectorSep 01Sale61.432,000122,86043,156Sep 02 05:45 PM
Cooke ShanePresident, Alkermes plcAug 24Option Exercise14.6018,000262,80058,640Aug 24 06:22 PM
Cooke ShanePresident, Alkermes plcAug 24Sale57.6518,0001,037,61740,640Aug 24 06:22 PM
FRATES JAMES MSVP & CFO, Alkermes plcAug 11Option Exercise14.3810,000143,80058,713Aug 12 05:50 PM
FRATES JAMES MSVP & CFO, Alkermes plcAug 11Sale67.9710,000679,74748,713Aug 12 05:50 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Aug 03Option Exercise16.5513,750227,56327,860Aug 04 05:29 PM
BREYER ROBERT ADirectorAug 03Sale69.612,000139,22045,156Aug 04 05:15 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Aug 03Sale70.0813,750963,55314,110Aug 04 05:29 PM
Cooke ShanePresident, Alkermes plcJul 23Option Exercise14.6018,000262,80058,640Jul 24 05:25 PM
Cooke ShanePresident, Alkermes plcJul 23Sale69.7918,0001,256,22540,640Jul 24 05:25 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jul 20Option Exercise33.7218,750632,25032,860Jul 21 05:19 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jul 20Sale70.1018,7501,314,40514,110Jul 21 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcJul 14Option Exercise13.0620,000261,20068,713Jul 15 05:08 PM
FRATES JAMES MSVP & CFO, Alkermes plcJul 14Sale65.7920,0001,315,86048,713Jul 15 05:08 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jul 01Option Exercise16.5513,750227,56327,860Jul 02 05:58 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jul 01Sale65.1313,750895,49914,110Jul 02 05:58 PM
BREYER ROBERT ADirectorJul 01Sale64.902,000129,80047,156Jul 02 05:51 PM
Cooke ShanePresident, Alkermes plcJun 23Option Exercise14.6018,000262,80058,640Jun 24 06:04 PM
Cooke ShanePresident, Alkermes plcJun 23Sale66.8418,0001,203,09840,640Jun 24 06:04 PM
MITCHELL PAUL JDirectorJun 17Option Exercise14.0415,500217,62023,500Jun 18 05:35 PM
MITCHELL PAUL JDirectorJun 17Sale65.1015,5001,009,0168,000Jun 18 05:35 PM
FRATES JAMES MSVP & CFO, Alkermes plcJun 16Option Exercise11.7410,000117,40058,713Jun 18 05:31 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jun 16Option Exercise17.4732,977576,05647,087Jun 18 05:34 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jun 16Sale63.1132,9772,081,24814,110Jun 18 05:34 PM
FRATES JAMES MSVP & CFO, Alkermes plcJun 16Sale58.6310,000586,34948,713Jun 18 05:31 PM
MITCHELL PAUL JDirectorJun 01Option Exercise14.041,50021,0609,500Jun 01 05:43 PM
BREYER ROBERT ADirectorJun 01Sale60.782,000121,56049,156Jun 01 05:45 PM
MITCHELL PAUL JDirectorJun 01Sale60.781,50091,1708,000Jun 01 05:43 PM
Peterson RebeccaSVP, Corporate CommunicationsJun 01Sale60.781,983120,5270Jun 01 05:40 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 28Option Exercise28.4023,750674,40020,000Jun 01 05:40 PM
Stejbach MarkChief Commercial OfficerMay 28Option Exercise0.002,500017,453May 29 06:16 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 28Option Exercise0.003,000015,523May 29 06:14 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 28Option Exercise0.002,5000139,858May 29 06:11 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 28Option Exercise0.003,750033,069May 29 06:09 PM
Cooke ShanePresident, Alkermes plcMay 28Option Exercise0.005,750043,630May 29 06:07 PM
BIBERSTEIN KATHRYN LSVP, CLO, Secretary & CCOMay 28Option Exercise0.003,750095,002May 29 06:04 PM
Brown Iain MichaelVP, Finance & CAOMay 28Option Exercise0.001,750038,178May 29 05:33 PM
FRATES JAMES MSVP & CFO, Alkermes plcMay 28Option Exercise0.002,500085,115Jun 01 07:31 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 28Sale59.9820,0001,199,5670Jun 01 05:40 PM
Cooke ShanePresident, Alkermes plcMay 26Option Exercise14.6018,000262,80055,880May 26 05:31 PM
Cooke ShanePresident, Alkermes plcMay 26Sale60.3118,0001,085,61537,880May 26 05:31 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 26Sale60.491,32279,9680May 26 05:05 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 22Sale61.111,05864,6540May 22 06:27 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 21Option Exercise16.5518,750310,31319,808May 22 06:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 21Option Exercise0.003,7500138,700May 22 06:00 PM
FRATES JAMES MSVP & CFO, Alkermes plcMay 21Option Exercise0.003,750084,382May 22 05:57 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 21Option Exercise0.004,500031,439May 22 05:47 PM
Cooke ShanePresident, Alkermes plcMay 21Option Exercise0.005,625040,805May 22 05:42 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.May 21Option Exercise0.004,500093,372May 22 05:39 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 21Option Exercise0.002,50002,500May 26 05:05 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 21Option Exercise0.004,125014,466May 22 06:31 PM